Ijeoma M Ifeorah

Dr. Ijeoma M Ifeorah

orcid
Assistant Professor

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
SSShemal M. Shah
Shemal M. Shah
HRHolly Rodin
Holly Rodin
HPHope Pogemiller
Hope Pogemiller
OMOluwadayo Magbagbeola
Oluwadayo Magbagbeola
KSKenneth Ssebambulidde
Kenneth Ssebambulidde
JDJose Debes
Jose Debes
Hepatitis B virus (HBV) vaccination patterns and the understanding of its risks among healthcare workers (HCWs) is a critical step to decrease transmission. However, the depth of this understanding is understudied. We distributed surveys to HCWs in 12 countries in Africa. Surveys had nine multiple-choice questions that assessed HCWs’ awareness and understanding of HBV. Participants included consultants, medical trainees, nurses, students, laboratory personnel, and other hospital workers. Surveys were completed anonymously. Fisher’s exact test was used for analysis, with a P-value of < 0.05 considered significant; 1,044 surveys were collected from Kenya, Egypt, Sudan, Tanzania, Ethiopia, Uganda, Malawi, Madagascar, Nigeria, Cameroon, Ghana, and Sierra Leone. Hepatitis B virus serostatus awareness, vaccination rate, and vaccination of HCWs’ children were 65%, 61%, and 48%, respectively. Medical trainees had higher serostatus awareness, vaccination rate, and vaccination of their children than HCWs in other occupations (79% versus 62%, P < 0.001; 74% versus 58%, P < 0.001; and 62% versus 45%, P = 0.006, respectively). Cost was cited as the most frequent reason for non-vaccination. West African countries were more aware of their serostatus but less often vaccinated than East African countries (79% versus 59%, P < 0.0001 and 52% versus 60%, P = 0.03, respectively). West African countries cited cost as the reason for non-vaccination more than East African countries (59% versus 40%, P = 0.0003). Our study shows low HBV serostatus awareness and vaccination rate among HCWs in Africa, and reveals gaps in the perception and understanding of HBV prevention that should be addressed to protect HCWs and improve their capacity to control HBV infection.

2 June 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
NQNasreen S. Quadri
Nasreen S. Quadri
ASAmir Sultan
Amir Sultan
SASophia Ibrahim Ali
Sophia Ibrahim Ali
MYMirghani Yousif
Mirghani Yousif
AMAbdelmajeed Moussa
Abdelmajeed Moussa
JDJose Debes
Jose Debes
: As coronavirus disease 2019 (COVID-19) spreads across Africa, little is known about the impact of the pandemic on health-care workers (HCWs) in the region. We designed an anonymous survey distributed via e-mail and phone messaging to 13 countries through the African Hepatitis B Network. We obtained 489 analyzable responses. We used risk ratio analysis to quantify the relationship between binary variables and χ2 testing to quantify the statistical significance of these relationships. Median age of respondents was 30 years (interquartile range, 26–36 years) and 63% were physicians. The top three sources of information used by HCWs for COVID-19 management included the Ministry of Health of each country, the WHO, and social media. Forty-nine percent reported a decrease in income since the start of the pandemic, with the majority experiencing between a 1% and a 25% salary reduction. Sixty-six percent reported some access to personal protective equipment; only 14% reported appropriate access. Moreover, one third of respondents reported no availability of ventilators at their facility. Strikingly, the percentage of HCWs reporting never feeling depressed changed from 61% before the pandemic to 31% during the pandemic, with a corresponding increase in daily depressive symptoms from 2% to 20%. Most respondents (> 97%) correctly answered survey questions about COVID-19 symptoms, virus transmission, and prevention. Our survey revealed African HCWs face a variety of personal and professional context-dependent challenges. Ongoing support of HCWs through and after the COVID-19 pandemic is essential.

31 July 2024 in Viruses
Verified
Journal Article
Open access
PDF file
Ijeoma M IfeorahIjeoma M Ifeorah
Ijeoma M Ifeorah
AGAthenaïs Gerber
Athenaïs Gerber
SDSamira Dziri
Samira Dziri
ABAdeleye Solomon Bakarey
Adeleye Solomon Bakarey
FGFrederic LE GAL
Frederic LE GAL
EGEmmanuel Gordien
Emmanuel Gordien
Hepatitis delta virus (HDV) is a satellite of hepatitis B virus (HBV), which requires the HBV surface antigen (HBsAg) for its assembly and propagation. Although countries affected by HBV infection in Africa are well identified, data on HDV infection are still scarce, like in Nigeria, where HBV infection is endemic. In this study, we aimed to determine the prevalence of HDV infection and identify the circulating genotypes/strains in the country. A nationwide study was performed on 1281 HBsAg-positive samples collected from patients across eleven sites drawn from the six geopolitical zones in Nigeria. Anti-HDV antibody (HDV-Ab) screening and HDV-RNA viral load quantification were performed using a commercial ELISA assay and real-time RT-PCR kit, respectively. HDV genotyping was performed by the Sanger sequencing of amplicons from the so-called R0 region of the viral genome, followed by phylogenetic analyses. Of the 1281 HBsAg-positive samples, 61 (4.8%) were HDV-Ab positive, among which, 12 (19.7%) were HDV-RNA positive. Genotypes were obtained for nine of them: seven “African” HDV-1, one “Asian/European” HDV-1 and one HDV-6. This study shows that Nigeria is a country of low HDV prevalence where mainly “African” genotype-1 strains are circulating.

1 April 2024 in Tropical Medicine and Health
Verified
Journal Article
Open access
PDF file
BOBabayemi O. Olakunde
Babayemi O. Olakunde
Ijeoma M IfeorahIjeoma M Ifeorah
Ijeoma M Ifeorah
DADaniel A. Adeyinka
Daniel A. Adeyinka
OOOlubunmi A. Olakunde
Olubunmi A. Olakunde
TOTemitayo Ogundipe
Temitayo Ogundipe
EEEchezona E. Ezeanolue
Echezona E. Ezeanolue
Background: Hepatitis B virus (HBV) infection in Africa is mostly acquired before the age of 5 years through vertical or horizontal routes. While all the countries in the World Health Organization African region have introduced HBV vaccination into their national immunization programs, the rate of protective immune response to HBV vaccine among children in Africa has not been systematically synthesized. In this study, we estimated the HBV vaccine seroprotection rate (defined as anti-HBs titer ≥ 10 IU/L) and the associated factors among under-five children who completed a primary series of HBV vaccination in Africa. Methods: We systematically searched PubMed, Web Science, and Scopus databases from inception to May 2022 for potentially eligible studies. The pooled seroprotection rate was estimated using a random-effects model with Freeman–Tukey double arcsine transformation and the associated factors were examined using odds ratio estimated by the DerSimonian and Laird method. Results: From the 1063 records identified, 29 studies with a total sample size of 9167 under-five children were included in the meta-analysis. The pooled seroprotection rate was 89.23% (95% CI 85.68–92.33%, I2 = 95.96%, p < 0.001). In the subgroup analyses, there was a significant difference in the rate by the assay method, vaccine dose, and vaccine combination. HIV-positive children had lower odds of achieving seroprotection when compared with HIV-negative children (OR = 0.22, 95%CI 0.12–0.40). Conclusions: The majority of under-five children in Africa achieved seroprotection after completing three or four doses of HBV vaccine. However, the rate was lower among children living with HIV. This calls for interventions to timely identify and address nonresponse to HBV vaccine, particularly among immunosuppressed children.

19 March 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
UGUwem Etop George
Uwem Etop George
TFTEMITOPE FALEYE
TEMITOPE FALEYE
LCLander De Coninck
Lander De Coninck
SASheriff Tunde Agbaje
Sheriff Tunde Agbaje
Ijeoma M IfeorahIjeoma M Ifeorah
Ijeoma M Ifeorah
Adewumi OlubusuyiAdewumi Olubusuyi
Adewumi Olubusuyi
Using a metagenomic sequencing approach on stool samples from children with Acute Flaccid Paralysis (AFP), we describe the genetic diversity of Sapoviruses (SaVs) in children in Nigeria. We identified six complete genome sequences and two partial genome sequences. Several SaV genogroups and genotypes were detected, including GII (GII.4 and GII.8), GIV (GIV.1), and GI (GI.2 and GI.7). To our knowledge, this is the first description of SaV infections and complete genomes from Nigeria. Pairwise identity and phylogenetic analysis showed that the Nigerian SaVs were related to previously documented gastroenteritis outbreaks with associated strains from China and Japan. Minor variations in the functional motifs of the nonstructural proteins NS3 and NS5 were seen in the Nigerian strains. To adequately understand the effect of such amino acid changes, a better understanding of the biological function of these proteins is vital. The identification of distinct SaVs reinforces the need for robust surveillance in acute gastroenteritis (AGE) and non-AGE cohorts to better understand SaVs genotype diversity, evolution, and its role in disease burden in Nigeria. Future studies in different populations are, therefore, recommended.

13 May 2019 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
Ijeoma M IfeorahIjeoma M Ifeorah
Ijeoma M Ifeorah
TFTEMITOPE FALEYE
TEMITOPE FALEYE
ABAdeleye Solomon Bakarey
Adeleye Solomon Bakarey
Adewumi OlubusuyiAdewumi Olubusuyi
Adewumi Olubusuyi
AGAthenais Gerber
Athenais Gerber
NONgozi F. Onyemelukwe
Ngozi F. Onyemelukwe